Is naltrexone (opioid receptor antagonist) a controlled substance?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 2, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Naltrexone Controlled Substance Status

Naltrexone is NOT a controlled substance and is unscheduled under the Controlled Substances Act, allowing any licensed physician to prescribe it without DEA restrictions. 1

Regulatory Classification

  • Naltrexone remains unscheduled because it is an opioid antagonist rather than an agonist, meaning it blocks opioid receptors rather than activating them, eliminating abuse potential. 1

  • This unscheduled status permits decentralized therapeutic approaches and ready prescribing access for motivated patients seeking opioid-free treatment options. 1

Contrast with Combination Products

  • While naltrexone alone is not controlled, phentermine-topiramate ER is classified as a schedule IV controlled substance due to the phentermine component's potential for abuse and dependence. 2

  • The naltrexone-bupropion ER combination is not classified as a controlled substance, as neither component has significant abuse potential—naltrexone blocks opioid effects and bupropion lacks the reinforcing properties of schedule IV stimulants. 2, 3

Clinical Implications of Unscheduled Status

  • The lack of controlled substance classification facilitates broader prescribing access, particularly beneficial for patients in outpatient settings who need separation from drug-using environments. 1

  • Prescribers do not need DEA registration or special licensing to prescribe naltrexone, unlike methadone or buprenorphine for opioid use disorder. 1

  • This regulatory advantage makes naltrexone particularly suitable for highly motivated patients preferring opioid-free treatment approaches, including healthcare professionals and criminal justice populations. 3

Important Prescribing Considerations

  • Despite being unscheduled, naltrexone requires patients to be completely opioid-free for 7-10 days before initiation to avoid precipitating severe withdrawal. 3, 4

  • Liver function monitoring is recommended at baseline and every 3-6 months, though hepatotoxicity at standard 50 mg doses has not emerged as a clinical problem. 3, 5

  • The unscheduled status does not eliminate the need for comprehensive addiction treatment—naltrexone works best as part of a larger therapeutic regimen with psychosocial support. 1, 6

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.